

# NEPHROTEST - NephroTest

Head :Stengel Bénédicte, INSERM U1018 CENTRE DE RECHERCHE EN ÉPIDÉMIOLOGIE ET SANTÉ DES POPULATIONS  
Froissart , UMR 872 EQ.3

Last update : 08/12/2014 | Version : 2 | ID : 60132

## General

### Identification

Detailed name	NephroTest
Sign or acronym	NEPHROTEST
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CPP 09298, CNIL DR 2010-149

### General Aspects

Medical area	Urology, andrology and nephrology
Keywords	renal function, glomerular filtration rate, vascular and metabolic complications, renal replacement therapy, Health episodes, quality of life, mortality

### Scientific investigator(s) (Contact)

Name of the director	Stengel
Surname	Bénédicte
Address	94807 VILLEJUIF CEDEX
Phone	+ 33 (0)1 45 59 50 39
Email	benedicte.stengel@inserm.fr
Unit	INSERM U1018 CENTRE DE RECHERCHE EN ÉPIDÉMIOLOGIE ET SANTÉ DES POPULATIONS
Organization	INSERM
Name of the director	Froissart
Address	75006 PARIS

Phone	+ 33 (0)1 56 09 39 73
Email	marc.froissart@parisdescartes.fr
Unit	UMR 872 EQ.3
Organization	INSERM

## Collaborations

## Funding

Funding status	Mixed
----------------	-------

Details	Ministère de la recherche, INSERM, Agence de Biomédecine, Laboratoires Roche, AMGEN
---------	---

## Governance of the database

Sponsor(s) or organisation(s) responsible	INSERM
Organisation status	Public

## Additional contact

## Main features

## Type of database

Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Prospective Inclusion cut-off date not determined

## Database objective

Main objective	General objective: To identify new biomarkers along with environmental and genetic risk factors for chronic kidney disease progression and related complications Secondary objectives: - To describe the natural history of chronic kidney disease in terms of optimised treatment according to
----------------	---

international recommendations - To evaluate the realisation and relevance of the recommended objectives (K/DOQI, KDIGO, HAS)

#### Inclusion criteria

Patients over 18 years of age with chronic kidney disease confirmed by the presence of kidney damage markers: biological, morphological or histological abnormalities and glomerular filtration rate measurement by reference method (renal clearance of <sup>51</sup>Cr-EDTA), stages 1-5 of the 2005 KDIGO classification, not on dialysis and not grafted.

#### Population type

##### Age

Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)

##### Population covered

Sick population

##### Gender

Male  
Woman

##### Geography area

Local

##### French regions covered by the database

Aquitaine Limousin Poitou-Charentes  
Île-de-France

##### Detail of the geography area

Multicentric cohort (3 centres) throughout France (Ile de France and Bordeaux)

#### Data collection

##### Dates

##### Date of first collection (YYYY or MM/YYYY)

01/2001

##### Date of last collection (YYYY or MM/YYYY)

12/2012

#### Size of the database

##### Size of the database (number of individuals)

[1000-10 000[ individuals

##### Details of the number of individuals

1835

#### Data

Database activity	Data collection completed
Type of data collected	Clinical data Declarative data Paraclinical data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Declarative data (detail)	Paper self-questionnaire Face to face interview
Paraclinical data (detail)	Imaging (pulse wave velocity, bioimpedance)
Biological data (detail)	Type of samples taken: blood and urine
Presence of a biobank	Yes
Contents of biobank	Serum Plasma Fluids (saliva, urine, amniotic fluid, ?) DNA
Details of biobank content	Serum bank, plasma bank, DNA bank, urine bank in progress
Health parameters studied	Health event/morbidity Health event/mortality Quality of life/health perception
<b>Procedures</b>	
Data collection method	Self-administered questionnaire: input from a paper questionnaire (manual input) Interview: input from a paper questionnaire (manual input) Clinical examinations handwritten (manual input) Biological analysis: direct input (Other) Other collection for biological analysis: direct import from laboratory data management system (interfaces)
Participant monitoring	Yes
Details on monitoring of participants	(Indefinite duration)
Links to administrative sources	Yes
Linked administrative sources (detail)	Pathology register
<b>Promotion and access</b>	

## Promotion

Link to the document <http://www.hal.inserm.fr/NEPHROTEST>

Description List of publications in HAL

Link to the document <http://tinyurl.com/Pubmed-NEPHROTEST>

Description List of publications in Pubmed

## Access

Terms of data access (charter for data provision, format of data, availability delay) Data may be used by academic teams Data may be used by industrial teams via the industrial steering committee

Access to aggregated data Access on specific project only

Access to individual data Access on specific project only